Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022Extended CRADA with the National... | March 30, 2022
Source: marketscreener.com